Fig. 2From: Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexateImpact on inflammation. Impact of a all agents, b tocilizumab, c adalimumab, d tofacitinib_0.1, and e tofacitinib_1.1 on soluble IL-6 receptor trans-signaling–mediated inflammation biologyBack to article page